Niigata Prefectural Central Hospital
In research, Niigata Prefectural Central Hospital stands highest in Health Sciences (#19,835 of 20,462 worldwide) and Medicine (#17,477 of 17,978 worldwide), over all time.
- World rank, all time
- #41,216 of 42,892
- Rank in Japan
- #1,986 of 2,112
- Research works
- 227 ▲ 52% vs 2013–17
- Citations
- 2k 9.0 per fractional work
- Top-10% rate
- 2.7% record average 16.5%
- Open access
- 42% world 28%
What is Niigata Prefectural Central Hospital known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Health SciencesDomain | #19,835 of 20,462 | 4.1% | 197 | |
| MedicineField | #17,477 of 17,978 | 4.1% | 195 |
Each strip is that field’s whole ranked pool, with the notch where Niigata Prefectural Central Hospital sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.6×. Every wedge is a field page.
Who are the top researchers at Niigata Prefectural Central Hospital?
Ranked on the composite score, Masao Sekiya lead among researchers whose main affiliation is Niigata Prefectural Central Hospital.
- 1 Masao Sekiya Japan · #1,029,226 worldwide 22 citations · 18 works
Which keywords describe research at Niigata Prefectural Central Hospital?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Chemotherapy, Immunotherapy, Neoadjuvant Therapy, Diagnosis, Clinical Practice Guidelines, Surgical Management and Tumor Microenvironment.
- Sorafenib
- Liver Cancer
- Complications
- Clinical Management
- Radiofrequency Ablation
- Mortality
- Cholangiocarcinoma
- Molecular Profiling
- Immunohistochemistry
- Gene Expression Profiling
- Sentinel Lymph Node Biopsy
- Hepatocellular Carcinoma
- Genetic Mutations
- Pancreatic Cancer
- Quality of Life
- Tumor Microenvironment
- Prognostic Factors
- Treatment
- Diagnosis
- Chemotherapy
- Epidemiology
- Immunotherapy
- Neoadjuvant Therapy
- Clinical Practice Guidelines
- Surgical Management
- Survival Analysis
- Management
- Surgical Complications
- Radiotherapy
- Metastatic Breast Cancer
- Clinical Trials
- Genetic Factors
- Metastasis
- Survival
- Imatinib Mesylate
- PET Imaging
- Breast Cancer
- Clinical Outcomes
- Dermoscopy
- Melanoma
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology7▲ 4.3×26 topics
- Chemotherapy4▲ 15×12 topics
- Immunotherapy4▲ 14×10 topics
- Diagnosis3▲ 7.9×9 topics
- Neoadjuvant Therapy3▲ 32×4 topics
- Treatment3▲ 5.4×7 topics
- Clinical Practice Guidelines3▲ 12×7 topics
- Prognostic Factors2▲ 14×6 topics
- Surgical Management2▲ 15×8 topics
- Tumor Microenvironment2▲ 14×4 topics
- Survival Analysis2▲ 22×5 topics
- Quality of Life2▲ 3.3×7 topics
- Management2▲ 5.8×5 topics
- Pancreatic Cancer2▲ 43×1 topic
- Surgical Complications2▲ 57×1 topic
- Genetic Mutations2▲ 9.8×6 topics
- Radiotherapy2▲ 11×5 topics
- Hepatocellular Carcinoma2▲ 18×2 topics
- Metastatic Breast Cancer1▲ 59×2 topics
- Sentinel Lymph Node Biopsy1▲ 39×2 topics
- Clinical Trials1▲ 4.3×6 topics
- Gene Expression Profiling1▲ 37×2 topics
- Genetic Factors1▲ 43×2 topics
- Immunohistochemistry1▲ 39×2 topics
- Metastasis1▲ 8.6×3 topics
- Molecular Profiling1▲ 30×2 topics
- Survival1▲ 22×2 topics
- Cholangiocarcinoma1▲ 33×2 topics
- Imatinib Mesylate1▲ 52×2 topics
- Mortality1▲ 4.6×4 topics
- PET Imaging1▲ 16×3 topics
- Radiofrequency Ablation1▲ 26×2 topics
- Breast Cancer1▲ 10×2 topics
- Clinical Management1▲ 15×3 topics
- Clinical Outcomes1▲ 12×2 topics
- Complications1▲ 5.1×7 topics
- Dermoscopy1▲ 57×1 topic
- Liver Cancer1▲ 45×1 topic
- Melanoma1▲ 41×1 topic
- Sorafenib1▲ 45×1 topic
Which research topics does Niigata Prefectural Central Hospital publish most on?
By volume in 2022–2025: Pancreatic and Hepatic Oncology Research, Cutaneous Melanoma Detection and Management, Hepatocellular Carcinoma Treatment and Prognosis and Cholangiocarcinoma and Gallbladder Cancer Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pancreatic and Hepatic Oncology Research Oncology 2 works
- 2 Cutaneous Melanoma Detection and Management Oncology 1 works
- 3 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 1 works
- 4 Cholangiocarcinoma and Gallbladder Cancer Studies Surgery 1 works
- 5 Cancer Diagnosis and Treatment Oncology 1 works
- 6 Pancreatitis Pathology and Treatment Surgery 1 works
- 7 Breast Cancer Treatment Studies Cancer Research 1 works
- 8 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 9 Acute Ischemic Stroke Management Epidemiology 1 works
- 10 Cancer Treatment and Pharmacology Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Niigata Prefectural Central Hospital's research output changed?
Output in 2018–2022 was 52% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Jōetsu
- Joetsu University of Education
- Niigata College of Nursing
- Saigata National Hospital
- Jōetsu General Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.